# Iryna Dyagil

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/786414/publications.pdf

Version: 2024-02-01

| 34 | 1,123 | 840776 | 501196 |
|---|---|---|---|
| papers | citations | 11 h-index | 28 g-index |

| 34 | 34 | 34 | 1331 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology, 2012, 30, 3486-3492. | 1.6 | 404 |
| 2 | Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology, 2018, 36, 231-237. | 1.6 | 356 |
| 3 | Radiation and the Risk of Chronic Lymphocytic and Other Leukemias among Chornobyl Cleanup Workers. Environmental Health Perspectives, 2013, 121, 59-65. | 6.0 | 106 |
| 4 | Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accidentâ€"With focus on immunoglobulin heavy chain gene analysis. Leukemia Research, 2008, 32, 535-545. | 0.8 | 28 |
| 5 | High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. Haematologica, 2010, 95, 908-913. | 3.5 | 28 |
| 6 | Epidemiology of Late Health Effects in Ukrainian Chornobyl Cleanup Workers. Health Physics, 2018, 115, 161-169. | 0.5 | 23 |
| 7 | An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Blood, 2010, 116, 208-208. | 1.4 | 23 |
| 8 | Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph+/BCR-ABL+ CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).. Blood, 2007, 110, 1048-1048. | 1.4 | 17 |
| 9 | Histologic Verification of Leukemia, Myelodysplasia, and Multiple Myeloma Diagnoses in Patients in Ukraine, 1987â€"1998. International Journal of Hematology, 2002, 76, 55-60. | 1.6 | 12 |
| 10 | DNA Repair Polymorphisms in B-cell Chronic Lymphocytic Leukemia in Sufferers of Chernobyl Nuclear Power Plant Accident. Journal of Radiation Research, 2012, 53, 497-503. | 1.6 | 12 |
| 11 | Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia. Blood, 2012, 120, 190-190. | 1.4 | 12 |
| 12 | Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers. Environmental Health, 2018, 17, 43. | 4.0 | 11 |
| 13 | Cancers after Chornobyl: From Epidemiology to Molecular Quantification. Cancers, 2019, 11, 1291. | 3.7 | 11 |
| 14 | Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. Blood, 2019, 134, 498-498. | 1.4 | 11 |
| 15 | High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial. Haematologica, 2012, 97, 1562-1569. | 3.5 | 10 |
| 16 | Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. Leukemia and Lymphoma, 2010, 51, 822-838. | 1.3 | 9 |
| 17 | Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. Blood, 2017, 130, 900-900. | 1.4 | 9 |
| 18 | Clinical characteristics of chronic lymphocytic leukemia occurring in chornobyl cleanup workers. Hematological Oncology, 2017, 35, 215-224. | 1.7 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Chronic Lymphocytic Leukemia in Chornobyl Cleanup Workers. Health Physics, 2016, 111, 186-191. | 0.5 | 6 |
| 20 | Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia. Leukemia Research, 2017, 58, 1-8. | 0.8 | 6 |
| 21 | Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up. Blood, 2017, 130, 896-896. | 1.4 | 6 |
| 22 | Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster. Leukemia, 2020, 34, 645-650. | 7.2 | 4 |
| 23 | CELSG CML 11 â€œISTAHITâ€•Phase III Study â€“ Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase.. Blood, 2008, 112, 1112-1112. | 1.4 | 3 |
| 24 | Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemiaâ€“BELA Trial. Blood, 2012, 120, 4442-4442. | 1.4 | 3 |
| 25 | Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. Blood, 2014, 124, 3160-3160. | 1.4 | 2 |
| 26 | CHRONIC MYELOID LEUKEMIA COURSE IN PERSONS EXPOSED TO IONIZING RADIATION AS A RESULT OF THE CHORNOBYL ACCIDENT. Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii, 2020, 25, 443-455. | 0.3 | 2 |
| 27 | CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. Blood, 2013, 122, 2735-2735. | 1.4 | 1 |
| 28 | Analysis of immunoglobulin heavy variable chain rearrangement in chronic lymphocytic leukemia patients among Chornobyl clean-up workers. Experimental Oncology, 2020, 42, 172-177. | 0.1 | 1 |
| 29 | CUMULATIVE INCIDENCE OF LYMPHOID AND MYELOID LEUKEMIAS IN DIFFERENT REGIONS OF THE CHERKASSY REGION IN 2001 AND 2014. , 2021, 2, 48-56. | 0.1 | 0 |
| 30 | The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. Leukemia Research, 2021, 110, 106686. | 0.8 | 0 |
| 31 | High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival â€“ Final Results of the CELSG Phase III CML11 â€œISTAHITâ€•Trial. Blood, 2010, 116, 2271-2271. | 1.4 | 0 |
| 32 | Busulfan Exposure Decrease CCyR Rate On Imatinib Therapy - Impact On Recent Pretreatment. Blood, 2011, 118, 4452-4452. | 1.4 | 0 |
| 33 | ÐÐ›Ð•Ð›Ð¬ÐÐ˜Ð™ ÐŸÐžÐ›Ð†ÐœÐŽÐÐÐ†Ð—Ðœ Ð¡Ð˜Ð¡Ð¢Ð•ÐœÐ˜ HLA Ð£ Ð¥Ð’ÐžÐÐ˜Ð¥ ÐÐ•Ð¥ÐÐžÐÐ†Ð§ÐÐ£ ÐœÐ†Ð„Ð›ÐžÐ‡Ð˜Ð | 0.1 | 0 |
| 34 | MYC copy number and mRNA expression in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chornobyl NPP accident. Experimental Oncology, 2020, 42, 60-65. | 0.1 | 0 |